

1 Richard Jaffe, Esq.
2 State Bar No. 289362
3 770 L Street, Suite 950
4 Sacramento, California 95814
5 Tel: 916-492-6038
6 Fax: 713-626-9420
7 [Email: rickjaffeesquire@gmail.com](mailto:rickjaffeesquire@gmail.com)

8 Robert F. Kennedy Jr., Esq.
9 (Subject to *pro hac vice* admission)
10 Children's Health Defense
11 1227 North Peachtree Parkway
12 Peachtree, Georgia 30269
13 Tel: 917-743-3868

14 **SUPERIOR COURT OF THE STATE OF CALIFORNIA**
15 **FOR THE COUNTY OF ALAMEDA**

16 CINDY KIEL, J.D., an Executive Associate Vice
17 Chancellor at UC Davis, MCKENNA
18 HENDRICKS, a UC Santa Barbara student,
19 EDGAR DE GRACIA, a UCLA student, and
20 LELAND VANDERPOEL, an employee at the
21 Fresno satellite extension of the UCSF Medical
22 Education Program, FRANCES OLSEN,
23 Professor of Law at UCLA,

24 Plaintiffs,

25 vs.

26 THE REGENTS OF THE UNIVERSITY OF
27 CALIFORNIA, a Corporation, and MICHAEL
28 V. DRAKE, in his official capacity as President
of the UNIVERSITY OF CALIFORNIA,

Defendants.

CASE NO. HG 20072843

**PETER DOSHI'S DECLARATION IN
SUPPORT OF PLAINTIFFS' MOTION
FOR A PRELIMINARY INJUNCTION**

UNLIMITED CIVIL JURISDICTION

DEPARTMENT 511

Date: October 14, 2020

Time: 1:30 PM

Reservation ID-2206283

Action Filed: August 27, 2020

Trial Date: None Set

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

I, Peter Doshi, declare as follows:

1. I submit this declaration in support of Plaintiffs’ Motion for a preliminary injunction. I have personal knowledge of the facts set forth herein and if called to testify, I could competently testify as follows:
2. I hold a PhD, and I am an Associate Professor (with tenure) in the Pharmaceutical Health Services Research Department at the University of Maryland School of Pharmacy.¹ I teach a required course in the PharmD curriculum, “Medical Evidence,” which trains students in skills necessary to critically appraise the scientific literature. I research the drug and vaccine approval process, how the risks and benefits of medical products are communicated, and how to improve the credibility and accuracy of evidence synthesis and biomedical publications. At the University of Maryland, I lead the [RIAT Support Center](#) which aims to accelerate the correction of the scientific record of clinical trials by making clinical trial publications more accurate and more complete, addressing these problems of publication bias and reporting bias. I have received national recognition for my work on clinical trial data transparency.²
3. I am also an associate editor of *The BMJ* (formerly, the British Medical Journal), which is roughly equivalent to the *Journal of the American Medical Association* here in the United States.³ (Attached as Exhibit “A” is a copy of my CV.)

¹ <https://faculty.rx.umaryland.edu/pdoshi/>

² <https://www.nytimes.com/2013/06/30/business/breaking-the-seal-on-drug-research.html>

³ <https://www.bmj.com/about-bmj/editorial-staff/peter-doshi>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

4. I am also a Cochrane review author, part of the team that reviewed the evidence base for neuraminidase inhibitors (anti-influenza drugs like oseltamivir/Tamiflu and zanamivir/Relenza).⁴
5. I am not affiliated with the defendants, plaintiffs, or lawyers involved in this or any other litigation on this matter and have not received any compensation, either directly or in-kind, for this affidavit. I am submitting this affidavit because the matter relates to my area of study and concerns me.
6. My credentials related to this specific topic of influenza vaccines are that I have studied influenza policy since around 2004. I have many peer reviewed publications on the topic (see Exhibit A), and my PhD dissertation⁵ is on the topic of CDC and WHO influenza control policies (primarily vaccines). As a testament to my reputation in this field, in 2013, I published a peer-reviewed article in *JAMA Internal Medicine* entitled “Influenza Vaccines: Time for a Rethink”. The editor in chief of the journal, a professor of medicine at University of California San Francisco, invited me to write this commentary article, considering me, in her words, “an expert in the field.”
7. In my opinion, there is an important gap between the science and policy of influenza, with adverse consequences for sound decision making. What I mean by this is that the scientific literature, taken as a whole and critically appraised, as researchers have done in Cochrane and other systematic reviews, demonstrates that the proven benefits of influenza vaccines are modest and information about adverse events has been insufficiently researched, particularly in certain populations such as children. Yet despite

⁴ <http://doi.org/10.1002/14651858.CD008965.pub4>

⁵ <http://dspace.mit.edu/handle/1721.1/69811>

1 this, public health officials and professional societies routinely justify their policies and
2 statement through selective (not systematic and thorough—and ultimately, inaccurate)
3 citations of the evidence base.

- 4 8. Consider Janet Napolitano’s executive order.⁶ In the executive order, the very first
5 assertion of evidence of influenza vaccines’ benefit hyperlinks to a CDC website which
6 prominently states: “Flu vaccines **have been shown** to reduce the risk of flu illness,
7 hospitalization, and death”⁷ (emphasis added). By using the phrase “have been shown,”
8 the CDC presents its claims as an unambiguous assertion of fact. But if one reads the
9 relevant technical document from the same agency, it is clear that CDC is aware that this
10 assertion of fact is unproven. To wit, in its report on influenza vaccines, the CDC’s
11 Advisory Committee on Immunization Practices (ACIP), the body which sets national
12 vaccination recommendations, clearly acknowledges that the studies in the literature that
13 have supported the view that influenza vaccines reduce complications, hospitalizations,
14 and save lives may be biased, which means the reported results may be unreliable. The
15 CDC ACIP document reads: “Influenza vaccination **might reduce** the frequency of
16 secondary complications and risk for influenza-related hospitalization and death among
17 community-dwelling adults aged ≥ 65 years with and without high-risk medical
18 conditions (160–164). However, these studies have been conducted using medical record
19 databases and did not use reductions in LCI illness as an outcome of interest. **Such**
20 **methods have been challenged** because results might not be adjusted adequately to
21
22
23
24

25 ⁶ <https://ucnet.universityofcalifornia.edu/news/2020/08/2020-21-flu-vaccination-executive-order.pdf>

26 ⁷ CDC (2020) “What are the benefits of flu vaccination?” <https://www.cdc.gov/flu/prevent/vaccine-benefits.htm>

1 control for the possibility that healthier persons might be more likely to be vaccinated
2 than less healthy persons (96,97,165–168)⁸ (emphasis mine). It should be noted that the
3 phrase “might reduce” was added; a *previous* version had presented the matter in more
4 certain terms: “Influenza vaccination ... reduces the risk for influenza-related
5 hospitalization and death....”⁹ The more circumspect “might reduce” language remains in
6 CDC’s technical documents to this day.¹⁰ Thus in its technical documents, CDC
7 acknowledges that there is no scientific certainty regarding what is arguably the most
8 important questions of influenza vaccine performance: *do influenza vaccines reduce*
9 *serious complications, hospitalizations, and mortality, particularly in the elderly which*
10 *experience most of the serious complications?* Despite this, on its website, the CDC
11 inaccurately presents the evidence as clear cut and definitive, and this CDC webpage was
12 subsequently cited as evidence in support of Janet Napolitano’s executive order. This is
13 an example of the gap between the science and the policy.

- 14
- 15
- 16 9. The executive order also highlights another type of gap between the evidence and policy
17 on influenza: public health agencies frequently only cite the articles that support their
18 view, and do not cite articles which do not support their view. For example, the CDC
19 ACIP recommendations mentioned above cited a study in the New England Journal of
20 Medicine which reported a large relative reduction in risk of death: 48%.¹¹ Yet
21 researchers have pointed out that these results are completely implausible as influenza is
22

23

24 ⁸ <https://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm>

25 ⁹ <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5908a1.htm>

26 ¹⁰ <https://www.cdc.gov/flu/professionals/acip/immunogenicity.htm>

27 ¹¹ Nichol KL, Nordin JD, Nelson DB, Mullooly JP, Hak E. Effectiveness of influenza vaccine in the
28 community-dwelling elderly. N Engl J Med 2007;357:1373-81

1 estimated to only cause around 5% of all wintertime deaths, as I explained in an article in
2 The BMJ.¹² Equally concerning is that the CDC does **not** cite or discuss a study with
3 similar results that reported influenza vaccination was associated with a 51% reduced
4 odds of death in patients hospitalized with pneumonia.¹³ The reason CDC does not cite
5 this latter study may be that this study found enormous benefit during the months that
6 influenza was not circulating—an obviously implausible finding. The reserach was done
7 to prove a point. As I explained in The BMJ, “the purpose of the study was to
8 demonstrate that the fantastic benefit they [the study authors’] expected to and did find—
9 and that others have found, such as the two studies that CDC cites—is simply
10 implausible, and likely the product of the ‘healthy-user effect’ (in this case, a propensity
11 for healthier people to be more likely to get vaccinated than less healthy people). Others
12 have gone on to demonstrate this bias to be present in other influenza vaccine studies.^{14 15}
13 Healthy user bias threatens to render the observational studies, on which officials’
14 scientific case rests, not credible.”¹⁶
15
16
17
18

19 ¹² Doshi P. Influenza: marketing vaccine by marketing disease. *BMJ* 2013;346:f3037
20 <https://www.bmj.com/content/346/bmj.f3037>

21 ¹³ Eurich DT, Marrie TJ, Johnstone J, Majumdar SR. Mortality reduction with influenza vaccine in
22 patients with pneumonia outside “flu” season: pleiotropic benefits or residual confounding? *Am J*
Respir Crit Care Med 2008;178:527-33.

23 ¹⁴ Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of
24 influenza vaccine effectiveness in seniors. *Int J Epidemiol* 2006;35:337-44. [Abstract/FREE Full Text](#)
[Google Scholar](#)

25 ¹⁵ Jackson LA, Nelson JC, Benson P, Neuzil KM, Reid RJ, Psaty BM, et al. Functional status is a
26 confounder of the association of influenza vaccine and risk of all cause mortality in seniors. *Int J*
Epidemiol 2006;35:345-52. [Abstract/FREE Full Text](#)[Google Scholar](#)

27 ¹⁶ Doshi P. Influenza: marketing vaccine by marketing disease. *BMJ* 2013;346:f3037
28 <https://www.bmj.com/content/346/bmj.f3037>

1 10. To assess whether influenza vaccines have any effect in reducing hospitalizations and
2 mortality, it is important to first understand who is hospitalized and dies with, or of,
3 influenza. An infection with influenza virus has, like Covid-19, a vastly different risk
4 profile depending on age. The vast majority of influenza-associated deaths occur in the
5 elderly. Death certificates for the United States show that of the 49,090 recorded
6 influenza deaths in the USA between 1999 and 2018 (using ICD-10 codes J10 and J11),
7 37,399 of these (or 76% of the 49,090) were in the elderly and 20,596 (or 42% of the
8 49,090) were in the 85+ years old population.¹⁷ Obviously, if one hopes to reduce
9 hospitalization, ICU, and death rates, one needs to be able to do it in the elderly
10 population. Yet, as I wrote in JAMA Internal Medicine, “In the last 4 decades, just 1
11 randomized controlled trial has successfully assessed influenza vaccines in the elderly
12 population living in the community, but only 10% of participants were 75 years or older,
13 and the trial was underpowered to detect differences in hospitalization or mortality.¹⁸”¹⁹
14 The Cochrane review of influenza vaccines in the elderly identified additional trials that
15 occurred in residential care settings, yet even with the additional data, the Cochrane
16 review concluded “Very few deaths occurred, and no data on hospitalisation were
17 reported.”²⁰ A non-Cochrane systematic review published in The Lancet Infectious
18
19
20

21 ¹⁷ <https://wonder.cdc.gov/controller/saved/D77/D84F318>

22 ¹⁸ Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza
23 vaccination in elderly individuals: a randomized double-blind placebo-controlled
24 trial. *JAMA*. 1994;272(21):1661-16657966893 [PubMed](#)

25 ¹⁹ Doshi P. Influenza Vaccines: Time for a Rethink. *JAMA Intern Med*. 2013;173(11):1014–1016.
26 doi:10.1001/jamainternmed.2013.490

27 ²⁰ Demicheli V, Jefferson T, Di Pietrantonj C, et al. Vaccines for preventing influenza in the elderly.
28 *Cochrane Database Syst Rev*. 2018;2(2):CD004876. Published 2018 Feb 1.
<https://doi.org/10.1002/14651858.CD004876.pub4>

1 Diseases came to similar conclusions about the evidence base, concluding: “Evidence for
2 protection in adults aged 65 years or older is lacking.”²¹

3 11. Assessing the efficacy of influenza vaccines is not as straightforward as it might be for
4 drugs. Unlike a drug, there is no single “flu shot” that we are testing in each study.

5 Influenza vaccines are not drugs, they are biologics. Variations in finished product can
6 occur from batch to batch, even of the same manufacturer. While companies may all
7 target the same influenza viruses, they do not all make the same product - they make
8 different products, with different manufacturing approaches, and different excipients.

9 With vaccines, there is no single small molecule active pharmaceutical ingredient that
10 manufacturers can all copy as generic drugs (once the patent has expired) and expect
11 similar efficacy and safety. And to add one more crucial variable of variation, as the
12 public knows, each year manufacturers alter their product, targeting a new virus. This is
13 one reason most people believe there is such marked variation between vaccine
14 performance from year to year—because the product getting tested is not a single, stable
15 product: it is constantly changing.

16
17
18 12. One implication of this is that influenza vaccines are put on the market each year without
19 knowing how effective or safe they will end up being. We can only find out after the fact.

20 This helps understand why both the benefits and risks (adverse events) can vary from
21 year to year, product to product, factory to factory.
22
23

24 ²¹ Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza
25 vaccines: a systematic review and meta-analysis [published correction appears in Lancet Infect Dis.
26 2012 Sep;12(9):655]. Lancet Infect Dis. 2012;12(1):36-44. [https://doi.org/10.1016/S1473-3099\(11\)70295-X](https://doi.org/10.1016/S1473-3099(11)70295-X)

1 13. The executive order also suffers from another common problem, which may be
2 unintentional, in policies around influenza: it repeatedly refers to influenza as “flu.”
3 Doing so conveys an illogical and unreasonably large expectation of the potential
4 beneficial impact of influenza vaccines. As I write in my 2013 BMJ article: “perhaps the
5 cleverest aspect of the influenza marketing strategy surrounds the claim that “flu” and
6 “influenza” are the same. The distinction seems subtle, and purely semantic. But general
7 lack of awareness of the difference might be the primary reason few people realize that
8 **even the ideal influenza vaccine, matched perfectly to circulating strains of wild**
9 **influenza and capable of stopping all influenza viruses, can only deal with a small**
10 **part of the “flu” problem because most “flu” appears to have nothing to do with**
11 **influenza.** Every year, hundreds of thousands of respiratory specimens are tested across
12 the US. Of those tested, on average 16% are found to be influenza positive. (fig 2).”²²
13 (Emphasis added.)

14
15 14. In any discussion of influenza vaccines, it is important to discuss the risk of side-effects,
16 including unexpected risks. Take the example of two “swine flu” H1N1 vaccines,
17 vaccines for which heightened surveillance was put in place. As governments around the
18 world prepared for a massive vaccination program to protect against a feared “second
19 wave” of H1N1, Anthony Fauci stated: “And apart for some minor issues which you'd
20 expect when you inject something into the arm of an individual, such as a swelling or
21 pain or some discomfort at the site, the track record for serious adverse events is very
22
23
24

25
26 ²² Doshi P. Influenza: marketing vaccine by marketing disease. *BMJ* 2013;346:f3037
<https://www.bmj.com/content/346/bmj.f3037>

1 good. It's very, very, very rare that you ever see anything that's associated with the
2 vaccine that's a severe event.”²³

3 15. That year, however, would witness the following, as I wrote about in *JAMA Internal*
4 *Medicine*: “Australia suspended its universal vaccination program for children younger
5 than 5 years because of a surge in febrile convulsions following vaccination (1 in 110
6 children).¹⁹ Also in 2009, cases of narcolepsy following vaccination in adolescents were
7 reported in Finland and Sweden. Official inquiries into these events have confirmed
8 influenza vaccine's role in all 3 countries, with the precise biological mechanisms still not
9 understood.²⁰⁻²²”²⁴ As I wrote subsequently, after investigating the case of Pandemrix
10 further, I should note in fairness that “GSK and the European Medicines Agency, which
11 licensed Pandemrix, have not accepted that the association with narcolepsy has been
12 proved to be causal, and research on the topic continues.¹⁴”²⁵ But the academic and
13 government led studies which judged the relationship between Pandemrix and narcolepsy
14 was likely to be causal have remained in the scientific literature.^{26 27 28}

17
18 ²³ Fauci A. “How Safe is the Flu Vaccine?” (2009)
<https://www.youtube.com/watch?v=TE4cNqcBCEQ>

19 ²⁴ Doshi P. Influenza Vaccines: Time for a Rethink. *JAMA Intern Med.* 2013;173(11):1014–1016.
doi:10.1001/jamainternmed.2013.490

20 ²⁵ Doshi P. Pandemrix vaccine: why was the public not told of early warning signs? *BMJ* 2018;
362:k3948

21 <https://www.bmj.com/content/362/bmj.k3948.full?ijkey=Q078zFNInyGN8CS&keytype=ref>

22 ²⁶ Partinen M, Saarenpää-Heikkilä O, Ilveskoski I, et al. Increased incidence and clinical picture of
23 childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. *PLoS*
One. 2012;7(3):e33723. doi:10.1371/journal.pone.0033723


24 ²⁷ Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an
25 abrupt increase in the incidence of childhood narcolepsy in Finland. *PLoS One.* 2012;7(3):e33536.
doi:10.1371/journal.pone.0033536

26 ²⁸ Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in children and young people receiving
27 AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. *BMJ.*
2013;346:f794. Published 2013 Feb 26. doi:10.1136/bmj.f794

1 16. I recount this information to provide evidence that it is wholly inaccurate to characterize
2 influenza vaccines as risk-free or better-than-nothing, a perception many may be left with
3 from the executive order which does not even discuss potential harms. The fact is that
4 for some people, influenza vaccines were clearly worse than nothing.

5 17. In my view, to support a mandate that requires individuals to receive an influenza
6 vaccine, there should be far more certainty about the evidence base. There should be at
7 least two randomized trials that both demonstrated influenza vaccines reduce
8 hospitalizations, ICU admissions, or mortality. But in reality, despite influenza vaccines
9 being recommended since 1960, there is not even a single randomized trial showing this.
10 The proven benefits should also be large enough that it can be confidently judged that
11 influenza vaccines will bring public health benefits far in excess of any potential harms.
12 The history of influenza vaccines does not support this premise.

13
14 18. I declare under penalty of perjury under the laws of the State of California that the
15 foregoing is true and correct and that this declaration was executed on September 15,
16 2020 in Howard County, Maryland.
17

18
19
20 
Peter Doshi, PhD

Curriculum Vitae of Peter Doshi, PhD

1) Biographical Information

A. Undergraduate Education

Brown University 1999 – 2002
Providence, Rhode Island
Bachelor of Arts
Anthropology

B. Graduate Education

Harvard University 2003 – 2006
Cambridge, Massachusetts
Master of Arts
Regional Studies—East Asia

Massachusetts Institute of Technology 2006 – 2011
Cambridge, Massachusetts
Doctor of Philosophy
History, Anthropology, and Science, Technology and Society

C. Postdoctoral Training

Johns Hopkins University School of Medicine 2011 – 2013
Baltimore, Maryland
Postdoctoral fellowship in Comparative Effectiveness Research
Divisions of General Pediatrics and General Internal Medicine

D. Employment Experience

University of Maryland School of Pharmacy
Assistant Professor of Pharmaceutical Health Services Research 2014 – 2019
Associate Professor of Pharmaceutical Health Services Research 2019 – present

BMJ 2013 – present
Associate Editor

Johns Hopkins University November 2012
Krieger School of Arts and Sciences
Part-time lecturer

2) Scholarly Activity

A. Publications in Refereed/Peer Reviewed Journals (Note: **Name of the faculty member in bold** and the corresponding author underlined. Students, residents, fellows, or post-docs supervised by the faculty member are indicated with an asterisk*)

1. **Doshi P**, Spence O*, Kuzucan A*, Powers JH 3rd. Communication of Nonefficacy Benefits of New Drugs Approved on the Basis of Noninferiority Trials Alone: Cohort Study of FDA and Sponsor Communication, 2011-2017. JAMA Intern Med. 2019;179(5):719–721. doi:10.1001/jamainternmed.2018.7040
2. Desai B*, Hong K*, Powers JH 3rd, **Doshi P**. Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling [published online ahead of print, 2019 Oct 28]. J Gen Intern Med. 2019;10.1007/s11606-019-05460-2. doi:10.1007/s11606-019-05460-2
3. Spence O*, Hong K*, Onwuchekwa Uba R*, **Doshi P**. Availability of study protocols for randomized trials published in high-impact medical journals: A cross-sectional analysis [published online ahead of print, 2019 Aug 26]. Clin Trials. 2019;1740774519868310. doi:10.1177/1740774519868310
4. **Doshi P**, Sieluk J*, Hung A*. The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us?. J Am Pharm Assoc (2003). 2019;59(2):195–201. doi:10.1016/j.japh.2018.12.003
5. Jefferson T, **Doshi P**, Boutron I, Golder S, Heneghan C, Hodgkinson A, Jones M, Lefebvre C, Stewart LA. When to include clinical study reports and regulatory documents in systematic reviews. BMJ Evid Based Med. 2018 Dec;23(6):210-217. doi: 10.1136/bmjebm-2018-110963. Epub 2018 Oct 11. PubMed PMID: 30309870.
6. Jørgensen L, **Doshi P**, Gøtzsche P, Jefferson T. Challenges of independent assessment of potential harms of HPV vaccines. BMJ. 2018 Sep 24;362:k3694. doi: 10.1136/bmj.k3694. PubMed PMID: 30249615.
7. **Doshi P**. Pandemrix vaccine: why was the public not told of early warning signs? BMJ. 2018 Sep 20;k3948. doi: 10.1136/bmj.k3948.
8. Jørgensen L, **Doshi P**, Gøtzsche P, Jefferson T. Challenges of independent assessment of potential harms of HPV vaccines. BMJ. 2018 Sep 24;k3694. doi: 10.1136/bmj.k3694.
9. Hodgkinson A, Dietz KC, Lefebvre C, Golder S, Jones M, **Doshi P**, et al. The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors. Systematic Reviews. 2018 Dec [cited 2018 Oct 2];7(1). doi: 10.1186/s13643-018-0766-x
10. Spence O*, Onwuchekwa Uba R*, Shin S*, **Doshi P**. Patient consent to publication and data sharing in industry and NIH-funded clinical trials. Trials 2018

May 3;19(1):269. doi: 10.1186/s13063-018-2651-2.

0 citations (Scopus), 55 social media mentions (PlumX Metrics), 4 readers on Mendeley (PlumX Metrics)

11. **Doshi P**, Hur P*, Jones M, Albarmawi H*, Jefferson T, Morgan DJ, et al. Informed consent to study purpose in randomized clinical trials of antibiotics, 1991 through 2011. *JAMA Intern Med* 2017;177(10):1452-1459.
4 citations (Scopus), 53 blog and social media mentions (Altmetric), 13 news outlet mentions (Altmetric), 9 readers on Mendeley (PlumX metrics), 7 full text views in EBSCO databases (PlumX Metrics), 342 PDF downloads from journal website
12. **Mayo-Wilson E**, Li T, Fusco N, Bertizzolo L, Canner JK, Cowley T, **Doshi P**, Ehmsen J, Gresham G, Guo N, Haythornthwaite JA, Heyward J, Hong H, Pham D, Payne JL, Rosman L, Stuart EA, Suarez-Cuervo C, Tolbert E, Twose C, Vedula S, Dickersin K. Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy. *J Clin Epidemiol* 2017 Nov;91:95-110.
3 citations (Scopus), 62 blog and social media mentions (PlumX Metrics), 11 readers on Mendeley (PlumX Metrics)
13. **Doshi P**. The unofficial vaccine educators: are CDC funded non-profits sufficiently independent? *BMJ* 2017 Nov 7;359:j5104.
0 citations (Scopus), 273 social media mentions (Altmetric), 4 readers on Mendeley (Altmetric), 1734 full text views on journal website, 205 PDF downloads from journal website
14. Sieluk J*, Palasik B*, dosReis S, **Doshi P**. ADHD medications and cardiovascular adverse events in children and adolescents: cross-national comparison of risk communication in drug labeling. *Pharmacoepidemiol Drug Saf* 2017 Mar;26(3):274-284.
0 citations (Scopus), 6 social media mentions (Altmetric), 3 readers on Mendeley (Altmetric)
15. **Spelsberg A**, Prugger C, **Doshi P**, Ostrowski K, Witte T, Husgen D, et al. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. *BMJ* 2017 Feb 7;356:j337.
3 citations (Scopus), 263 blog and social media mentions (Altmetric), 7 news outlet mentions (Altmetric), 21 readers on Mendeley (Altmetric), 18,941 full text views on journal website, 1927 PDF downloads from journal website, 9 user-generated Bitly links to article with a total of 200 link clicks (PlumX Metrics)
16. **Doshi P**, Jefferson T. Open data 5 years on: A case series of 12 freedom of information requests for regulatory data to the European Medicines Agency. *Trials* 2016;17(1).
9 citations (Scopus), 59 blog and social media mentions (Altmetric), 15 readers on Mendeley (PlumX Metrics), 10 full text views in EBSCO databases (PlumX Metrics), 8 user-generated Bitly links to article with a total of 99 link clicks (PlumX Metrics)

17. **Doshi P.** Is this trial misreported? Truth seeking in the burgeoning age of trial transparency. *BMJ* 2016 Oct 24;355:i5543.
2 citations (Scopus), 59 blog and social media mentions (Altmetric), 10 readers on Mendeley (Altmetric), 1761 full text views on journal website, 239 PDF downloads from journal website
18. **Heneghan CJ**, Onakpoya I, Jones MA, **Doshi P**, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Mahtani KR, Nunan D, Howick J, Jefferson T. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. *Health Technol Assess* 2016 May;20(42):1-242.
10 citations (Scopus), 84 blog and social media mentions (Altmetric), 1 news outlet mention (PlumX Metrics) 1 policy document mention (Altmetric), 46 readers on Mendeley (Altmetric), 1 Wikipedia reference (PlumX Metrics)
19. **Doshi P.** Data too important to share: do those who control the data control the message? *BMJ* 2016 Mar 2;352:i1027.
13 citations (Scopus), 93 blog and social media mentions (Altmetric), 4 news outlet mentions (Altmetric), 20 readers on Mendeley (Altmetric), 9127 full text views on journal website, 1086 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 5 link clicks (PlumX Metrics)
20. **Persaud N, Doshi P.** North American regulatory agencies can and should make clinical trial data publicly available. *CMAJ* 2016 Feb 2;188(2):96-97.
5 citations (Scopus), 21 blog and social media mentions (Altmetric), 1 reader on Mendeley (Altmetric), 1 full text view in EBSCO databases (PlumX Metrics)
21. Hung A*, Sieluk J*, **Doshi P.** The Untapped Potential of Pharmacy Leaflets for Informing Patients About Drug Benefits and Risks. *JAMA Intern Med* 2016 Jan;176(1):11-12.
1 citation (Scopus), 87 blog and social media mentions (Altmetric), 9 readers on Mendeley (Altmetric), 1 full text view in EBSCO databases (PlumX Metrics), 517 PDF downloads from journal website
22. **Doshi P.** Defining antibiotic effectiveness and resistance: how a private party may soon rule judgments over susceptibility testing. *BMJ* 2016 Jan 6;352:h6849.
0 citations (Scopus), 19 social media mentions (Altmetric), 3 readers on Mendeley (Altmetric), 733 full text views on journal website, 168 PDF downloads from journal website
23. **Mayo-Wilson E**, Hutfless S, Li T, Gresham G, Fusco N, Ehmsen J, Heyward J, Vedula S, Lock D, Haythornthwaite J, Payne JL, Cowley T, Tolbert E, Rosman L, Twose C, Stuart EA, Hong H, **Doshi P**, Suarez-Cuervo C, Singh S, Dickersin K. Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: A protocol for a systematic review. *Syst Rev* 2015;4(1).
2 citations (Scopus), 13 social media mentions (Altmetric), 22 readers on Mendeley (Altmetric)

24. Mayo-Wilson E, Doshi P, Dickersin K. Are manufacturers sharing data as promised? *BMJ* 2015 Sep 25;351:h4169.
6 citations (Scopus), 57 blog and social media mentions (Altmetric), 4 readers on Mendeley (Altmetric), 974 full text views on journal website, 211 PDF downloads from journal website
25. Doshi P. Speeding new antibiotics to market: a fake fix? *BMJ* 2015 Mar 25;350:h1453.
14 citations (Scopus), 150 blog and social media mentions (Altmetric), 2 news outlet mentions (Altmetric), 25 readers on Mendeley (Altmetric), 6165 full text views on journal website, 811 PDF downloads from journal website, 2 full text views in EBSCO databases (PlumX Metrics), 6 user-generated Bitly links to article with a total of 286 link clicks (PlumX Metrics)
26. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. *Cochrane Database Syst Rev* 2014;2014(4).
128 citations (Scopus), 398 blog and social media mentions (Altmetric), 37 news outlet mentions (Altmetric), 188 readers on Mendeley (Altmetric), 1 policy document reference (Altmetric), 5 Wikipedia references (Altmetric), 4 YouTube video mentions (Altmetric), 9 user-generated Bitly links to article with a total of 32 link clicks (PlumX Metrics)
27. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, et al. Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports. *BMJ Open* 2014 Sep 30;4(9):e005253-2014-005253.
8 citations (Scopus), 88 blog and social media mentions (Altmetric), 1 news outlet mention (Altmetric), 23 readers on Mendeley (Altmetric), 1 policy document reference (Altmetric), 4490 full text views on journal website, 567 PDF downloads from journal website, 9 user-generated Bitly links to article with a total of 18 link clicks (PlumX Metrics)
28. Jefferson T, Doshi P. Multisystem failure: the story of anti-influenza drugs. *BMJ* 2014 Apr 10;348:g2263.
31 citations (Scopus), 26 blog and social media mentions (Altmetric), 33 readers on Mendeley (Altmetric), 1 Wikipedia reference (PlumX Metrics) 5952 full text views on journal website, 1344 PDF downloads from journal website, 5 user-generated Bitly links to article with a total of 3 link clicks (PlumX Metrics)
29. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. *BMJ* 2014 Apr 9;348:g2545.
106 citations (Scopus), 776 blog and social media mentions (Altmetric), 32 news outlet mentions (Altmetric), 156 readers on Mendeley (Altmetric), 2 Wikipedia references (PlumX Metrics), 105,987 full text views on journal website, 18,869 PDF downloads from journal website, 1 full text view in EBSCO databases

- (PlumX Metrics), 26 user-generated Bitly links to article with a total of 139 link clicks (PlumX Metrics)*
30. **Doshi P**, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: A call for people to publish the findings. *BMJ* 2013;346(7913). *78 citations (Scopus), 336 blog and social media mentions (Altmetric), 47 news outlet mentions (Altmetric), 1 Wikipedia reference (PlumX Metrics), 89 readers on Mendeley (Altmetric), 56,338 full text views on journal website, 5169 PDF downloads from journal website, 19 user-generated Bitly links to article with a total of 134 link clicks (PlumX Metrics)*
 31. **Doshi P**. Influenza vaccines: time for a rethink. *JAMA Intern Med* 2013 Jun 10;173(11):1014-1016. *10 citations (Scopus), 95 social media mentions (Altmetric), 1 news outlet mention (PlumX Metrics), 19 readers on Mendeley (Altmetric), 1 full text view in EBSCO databases (PlumX Metrics), 972 PDF downloads from journal website, 4 user-generated Bitly links to article with a total of 2 link clicks (PlumX Metrics)*
 32. **Doshi P**, Jefferson T. The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer. *JAMA Intern Med* 2013 Mar 11;173(5):380-382. *19 citations (Scopus), 3 blog mentions (Altmetric), 10 readers on Mendeley (Altmetric), 4 full text views in EBSCO databases, 1079 PDF downloads from journal website, 2 user-generated Bitly links to article with a total of 1 link click (PlumX Metrics)*
 33. **Doshi P**, Jefferson T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. *BMJ Open* 2013 Feb 26;3(2):10.1136/bmjopen-2012-002496. Print 2013. *38 citations (Scopus), 57 blog and social media mentions (Altmetric), 1 policy document reference (Altmetric), 18 readers on Mendeley (Altmetric), 10,343 full text views on journal website, 1558 PDF downloads from journal website*
 34. **Doshi P**, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. *PLoS Med* 2012;9(4):e1001201. *95 citations (Scopus), 117 blog and social media mentions (journal website), 141 readers on Mendeley (Mendeley.com), 1 Wikipedia reference (PlumX Metrics), 62,915 full text views on journal website, 5459 PDF downloads from journal website and PubMed Central, 1 user-generated Bitly link to article with a total of 3 link clicks (PlumX Metrics)*
 35. Jefferson T, Jones MA, **Doshi P**, Del Mar CB, Heneghan CJ, Hama R, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Cochrane Database Syst Rev* 2012 Jan 18;1:CD008965. *89 citations (Scopus), 66 blog and social media mentions (Altmetric), 7 news outlet mentions (Altmetric), 99 readers on Mendeley (Altmetric), 3 Wikipedia references (PlumX Metrics), 1 YouTube video mentions (Altmetric)*

36. **Doshi P**, Jones M, Jefferson T. Rethinking credible evidence synthesis. *BMJ* 2012 Jan 17;344:d7898.
39 citations (Scopus), 26 blog and social media mentions (Altmetric), 58 readers on Mendeley (Altmetric), 1 policy document reference (Altmetric), 11,133 full text views on journal website, 1832 PDF downloads from journal website
37. **Doshi P**. The elusive definition of pandemic influenza. *Bull World Health Organ* 2011 Jul 1;89(7):532-538.
40 citations (Scopus), 41 readers on Mendeley (PlumX Metrics), 515 full text views in EBSCO databases (PlumX Metrics)
38. Jefferson T, **Doshi P**, Thompson M, Heneghan C, Cochrane Acute Respiratory Infections Group. Ensuring safe and effective drugs: who can do what it takes? *BMJ* 2011 Jan 11;342:c7258.
37 citations (Scopus), 12 blog and social media mentions (Altmetric), 2 news outlet mentions (Altmetric), 38 readers on Mendeley (Altmetric), 7022 full text views on journal website, 11 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 109 link clicks (PlumX Metrics)
39. Jefferson T, Jones M, **Doshi P**, Del Mar C, Dooley L, Foxlee R. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. *Cochrane Database Syst Rev* 2010 Feb 17;(2):CD001265. doi(2):CD001265.
60 citations (Scopus), 2 blog and social media mentions (Altmetric), 14 readers on Mendeley (Altmetric)
40. **Doshi P**. Neuraminidase inhibitors--the story behind the Cochrane review. *BMJ* 2009 Dec 8;339:b5164.
58 citations (Scopus), 47 blog and social media mentions (Altmetric), 4 news outlet mentions (Altmetric), 52 readers on Mendeley (Altmetric), 14,332 full text views on journal website, 7 PDF downloads from journal website
41. Jefferson T, Jones M, **Doshi P**, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. *BMJ* 2009 Dec 8;339:b5106.
209 citations (Scopus), 45 blog and social media mentions (Altmetric), 5 news outlet mentions (Altmetric), 2 Wikipedia references (Altmetric), 101 readers on Mendeley (Altmetric), 79,183 full text views on journal website, 13,916 PDF downloads from journal website, 7 full text views in EBSCO databases (PlumX Metrics), 2 user-generated Bitly links to article with a total of 1 link click (PlumX Metrics)
42. **Doshi P**. Calibrated response to emerging infections. *BMJ* 2009 Sep 3;339:b3471.
63 citations (Scopus), 2 blog mentions (Altmetric), 1 Wikipedia reference (PlumX Metrics), 8 readers on Mendeley (Altmetric), 9667 full text views on journal website, 30 PDF downloads from journal website
43. **Doshi P**. Trends in recorded influenza mortality: United States, 1900-2004. *Am J*

Public Health 2008 May;98(5):939-945.

48 citations (Scopus), 11 social media mentions (Altmetric), 3 news outlet mentions (Altmetric), 37 readers on Mendeley (Altmetric), 3466 full text views in EBSCO databases (PlumX Metrics)

B. Presentations at Scientific or Professional Meetings

(Note: **Name of the faculty member in bold**. Students, residents, fellows, or post-docs supervised by the faculty member are indicated with an asterisk*)

1. **Doshi P.** The BMJ Investigative Journalism Conference. "Standards for drug approval: too stringent, too lax, or just right?" Berlin, Germany. November 18, 2019
Presentation; International; Podium
2. **Doshi P.** Friends of the National Library of Medicine conference. "Better clinical trials for new product development" Bethesda, MD. June 14, 2017
Invited presentation; National; Podium
3. **Doshi P.** "The gain to be realized by research transparency." 2016 Consumers United for Evidence-based Health Care annual meeting July 29, 2016, Washington DC
Invited presentation; National; Podium
4. **Doshi P,** Sieluk J*, Hung A*. "The Possible Harms of Statins: What do Product Labels and Pharmacy Leaflets Tell Us?" AACP Annual Meeting, Anaheim, CA. July 2016;
Invited presentation; National; Poster
5. **Doshi P.** Johns Hopkins School of Public Health. "The Hopkins mandatory flu vaccination policy, the search for truth, and freedom of speech in an academic institution" Baltimore, MD. June 10, 2016
Invited presentation; Local; Podium
6. **Doshi P.** "Adaptive Licensing & Access to Data" webcast presentation to European Public Health Alliance, Brussels, Belgium. April 18, 2016
Invited presentation; International; Webcast
7. **Doshi P.** "Speeding new antibiotics to market: a fake fix?", National Physicians Alliance annual meeting. Washington, DC.; October 17, 2015
Invited presentation; National; Podium
8. **Doshi P.** "How CUE can engage lay journalists", 2015 Consumers United for Evidence-based Health Care annual meeting, July 24, 2015. Washington, DC
Invited presentation; National; Podium
9. **Doshi P.** "Good and Bad Reanalysis", Society for Clinical Trials. May 19, 2015. Washington, DC
Invited presentation; National; Podium

10. **Doshi P.** “How Open Data Can Reduce Reporting Biases and Help Patients Choose Wisely,” Global Health & Innovation Conference. March 29, 2015, New Haven, CT
Invited presentation; National; Podium
11. **Doshi P.** “Who wants my data and what are they going to do with it?”, Consumers United for Evidence-based Healthcare (CUE) annual meeting, Washington D.C., July 25, 2014
Invited presentation; Non-reviewed; National; Podium
12. **Doshi P.** “Searching for evidence under the waterline”, Health Technology Assessment International (HTAi) annual meeting, Washington, DC, June 18, 2014
Invited presentation; International; Podium
13. **Doshi P.** “‘Open’ access to clinical trials: rhetoric and fine print”, Society for Clinical Trials annual meeting, Philadelphia, May 19, 2014
Invited presentation; National; Podium
14. **Doshi P.** “Thoughts on misleading analyses”, Presentation at Institute of Medicine consensus study meeting, February 4, 2014
Invited presentation; National; Podium
15. **Doshi P.** “Restoring Invisible and Abandoned Trials: the RIAT concept”, presentation at CBI conference on Clinical Data Disclosure and Transparency, January 30, 2014
Invited presentation; National; Podium
16. **Doshi P.** “Restoring Invisible and Abandoned Trials: the RIAT concept”, presentation at “The state of contemporary biomedical literature” conference sponsored by age.na.s, Rome, Italy, December 12, 2013
Invited presentation; International; Podium
17. **Doshi P.** “Restoring Invisible and Abandoned Trials: the RIAT concept”, presentation at oPen conference, Naples, Italy, December 13, 2013
Invited presentation; International; Podium
18. **Doshi P.** “Credible evaluation of trials: what kind of data do we need?”, Presentation at Institute of Medicine workshop on sharing clinical research data, October 5, 2012
Invited presentation; National; Podium
19. **Doshi P, Bass E.** “Do media understand that systematic reviews are not just another ‘new study’?” 18th Annual National Research Services Award (NRSA) Conference; June 23, 2012
Presentation; National; Poster

C. Special Lectures (Invited)

1. "Working with regulatory data – a non-regulatory, non-industry perspective" Presentation to closed FDA-Health Canada meeting, Silver Spring, November 13, 2018; Invited lecture.
2. "Better evidence for better health" Presentation to WHO Uppsala Monitoring Centre 40th Anniversary, Uppsala, Sweden; May 17, 2018; Invited lecture
3. "The RIAT Initiative for Tackling Bias in Biomedical Literature" Presentation to National Library of Medicine ClinicalTrials.gov team, March 5, 2018; Invited lecture.
4. "Interim guidance on how to decide whether to include clinical study reports and other regulatory documents into Cochrane reviews" Presentation to Cochrane Scientific Committee, by web, February 28, 2018; Invited lecture
5. "Ensuring Accuracy in Clinical Trial Publications: Weighing Options" Continuing medical education lecture, Food and Drug Administration. Silver Spring, MD. October 25, 2017; Invited lecture
6. Office of Research Integrity conference "Quest for Research Excellence". Washington, DC. August 9, 2017; Panel Participation
7. "Why we need clinical trial data, and how FDA can help reduce abuse of the medical literature" Food and Drug Administration, Silver Spring, MD. June 6, 2017; Invited lecture
8. "Ensuring accuracy in clinical trial publications: weighing options" online webcast through University of Maryland M-CERSI program. April 20, 2017; Invited lecture
9. "Ensuring accuracy in clinical trial publications: weighing options" Food and Drug Administration, Silver Spring, MD. March 14, 2017; Invited lecture
10. "Finding "Big Data" (OK, big detail) under the waterline" Johns Hopkins University, Baltimore, MD. January 27, 2017; Invited lecture
11. "How We Fooled Ourselves into Thinking the Revolution on Data Transparency Was Won," Johns Hopkins Center for Clinical Trials seminar series January 6, 2016; Invited lecture
12. "The NYAG's contribution to evidence-based medicine," New York State Attorney General's Office. New York, NY; November 9, 2015; Invited lecture
13. "Breaking the Seal on Drug Company Research", presentation at Des Moines University "Leadership series" seminar, Des Moines, Iowa; September 18, 2014; Invited lecture
14. Dean's Convocation panel on "Big Data." University of Maryland School of Law; September 22, 2014; Panel participation

D. Other Publications and Related Activities

1. Publications not peer reviewed

1. Lexchin J, Herder M, **Doshi P**. Canada finally opens up data on new drugs and devices. *BMJ*. 2019;365:l1825. Published 2019 Apr 17. doi:10.1136/bmj.l1825
2. **Doshi P**. EMA scales back transparency initiatives because of workload. *BMJ* 2018;362:k3513. doi: 10.1136/bmj.k3513.
3. **Doshi P**, Shamseer L*, Jones M, Jefferson T. Restoring biomedical literature with RIAT. *BMJ* 2018 Apr 26;361:k1742. doi: 10.1136/bmj.k1742.
0 citations (Scopus), 60 social media mentions (Altmetric), 1 reader on Mendeley (Altmetric), 118 PDF downloads from journal website
4. **Doshi P**. EMA recommendation on hydroxyethyl starch solutions obscured controversy. *BMJ* 2018 Mar 20;360:k1287. doi: 10.1136/bmj.k1287.
1 citation (Scopus), 22 blog and social media mentions (Altmetric), 1 reader on Mendeley (Altmetric), 161 PDF downloads from journal website
5. **Doshi P**. CDC tightens controls on scientists' communication with news media. *BMJ* 2018 Feb 14;360:k675.
0 citations (Scopus), 5 social media mentions (Altmetric), 3 news outlet mentions (Altmetric), 4 readers on Mendeley (Altmetric), 403 full text views on journal website, 63 PDF downloads from journal website
6. **Doshi P**. FDA to begin releasing clinical study reports in pilot programme. *BMJ* 2018 Jan 23;360:k294.
0 citations (Scopus), 47 blog and social media mentions (Altmetric), 294 full text views on journal website, 61 PDF downloads from journal website
7. **Doshi P**. "Independent" reanalysis of landmark starch solutions trial was published by original authors. *BMJ* 2017 Jul 21;358:j3552.
0 citations (Scopus), 96 blog and social media mentions (Altmetric), 2 news outlet mentions (Altmetric), 2 readers on Mendeley (Altmetric), 2536 full text views on journal website, 274 PDF downloads from journal website
8. **Doshi P**. The problem with US website for collecting adverse events after vaccination is resolved. *BMJ* 2017 Sep 8;358:j4164.
0 citations (Scopus), 133 social media mentions (Altmetric), 131 full text views on journal website, 46 PDF downloads from journal website
9. **Doshi P**. US government website for collecting adverse events after vaccination is inaccessible to most users. *BMJ* 2017;357.
0 citations (Scopus), 325 social media mentions and interactions (PlumX Metrics), 2 news outlet mentions (PlumX Metrics), 550 full text views on journal website, 67 PDF downloads from journal website
10. **Doshi P**, Godlee F. The wider role of regulatory scientists. *BMJ* 2017 Apr

27;357;j1991.

4 citations (Scopus), 45 blog and social media mentions (Altmetric), 3 readers on Mendeley (Altmetric), 1224 full text views on journal website, 216 PDF downloads from journal website

11. **Doshi P.** FDA unease about faster drug approval. *BMJ* 2017;357.
2 citations (Scopus), 124 blog and social media mentions (Altmetric), 1 news outlet mention (Altmetric), 3 readers on Mendeley (Altmetric), 908 full text views on journal website, 169 PDF downloads from journal website
12. **Doshi P.** Medical response to Trump requires truth seeking and respect for patients. *BMJ* 2017 Feb 7;356:j661.
0 citations (Scopus), 188 blog and social media mentions (Altmetric), 2 news outlet mentions (Altmetric), 3 readers on Mendeley (Altmetric), 8710 full text views on journal website, 147 PDF downloads from journal website
13. **Doshi P.** Update: New England journal of medicine publishes correction to 2012 chest trial of hydroxyethyl starch versus colloids. *BMJ* 2016;352.
3 citations (Scopus), 4 social media mentions (Altmetric), 2 readers on Mendeley (Altmetric), 653 full text views on journal website, 233 PDF downloads from journal website
14. **Zito JM, Doshi P.** For-profit Uses of Real-World Data: What Would Frances Kelsey Do? *Med Care* 2016 Dec;54(12):1045-1047.
3 citations (Scopus), 1 social media mention (Altmetric), 2 readers on Mendeley (Altmetric)
15. **Doshi P.** FDA drug summaries: a simplification too far? *BMJ* 2015 Jun 12;350:h3135.
0 citations (Scopus), 14 social media mentions (Altmetric), 1 news outlet mention (Altmetric), 4 readers on Mendeley (Altmetric), 665 full text views on journal website, 181 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 4 link clicks (PlumX Metrics)
16. **Doshi P.** Convicting Zika. *BMJ* 2016 Apr 7;353:i1847.
4 citations (Scopus), 79 social media mentions (Altmetric), 52 readers on Mendeley (Altmetric), 17,401 full text views on journal website, 1085 PDF downloads from journal website, 4 user-generated Bitly links to article with a total of 39 link clicks (PlumX Metrics)
17. **Doshi P,** Jefferson T. The evidence base for new drugs: New legislation in germany provides another piece of a complex puzzle. *BMJ* 2015;350.
0 citations (Scopus), 61 blog and social media mentions (Altmetric), 1 news outlet mention (Altmetric), 1 reader on Mendeley (Altmetric), 1 Wikipedia reference (PlumX Metrics), 1118 full text views on journal website, 474 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 1 link click (PlumX Metrics)
18. **Doshi P,** Stahl-Timmins W, Merino JG, Simpkins C. Visualising childhood

vaccination schedules across G8 countries. *BMJ* 2015;351.
2 citations (Scopus), 17 social media mentions (Altmetric), 6 readers on Mendeley (Altmetric), 1331 full text views on journal website, 272 PDF downloads from journal website, 1 user-generated Bitly link to article with a total of 1 link click (PlumX Metrics)

19. Jones M, Jefferson T, **Doshi P**, Del Mar C, Heneghan C, Onakpoya I. Commentary on Cochrane review of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Clin Microbiol Infect* 2015;21(3):217-221.
5 citations (Scopus), 2 social media mentions (PlumX Metrics)
20. **Doshi P**. No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility. *BMJ* 2015 Sep 16;351:h4629.
16 citations (Scopus), 535 blog and social media mentions (Altmetric), 52 news outlet mentions (Altmetric), 46 readers on Mendeley (Altmetric), 21,165 full text views on journal website, 2473 PDF downloads from journal website, 18 user-generated Bitly links to article with a total of 266 link clicks (PlumX Metrics)
21. **Doshi P**. 21st century cures: is US medicines bill a colossal mistake? *BMJ* 2015 Jul 23;351:h4013.
3 citations (Scopus), 66 blog and social media mentions (Altmetric), 1 news outlet mention (Altmetric), 6 readers on Mendeley (Altmetric), 1563 full text views on journal website, 127 PDF downloads from journal website, 1 user-generated Bitly link to article with a total of 2 link clicks (PlumX Metrics)
22. **Doshi P**. No vote in US Congress on proposal to create new pathway for approving antibiotics. *BMJ* 2015 Mar 31;350:h1767.
0 citations (Scopus), 3 social media mentions (Altmetric), 1 news outlet mention (Altmetric), 152 full text views on journal website, 60 PDF downloads from journal website
23. **Doshi P**, Zito J, DosReis S. Digging for data on harms in duloxetine trials: It's time for policy makers to get serious about drug related harms. *BMJ* 2014;348.
2 citations (Scopus), 6 blog and social media mentions (Altmetric), 16 readers on Mendeley (Altmetric), 1092 full text views on journal website, 363 PDF downloads from journal website
24. Jefferson T, Jones MA, **Doshi P**, Del Mar CB, Hama R, Thompson M, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Sao Paulo Med J* 2014;132(4):256-257.
2 citations (Scopus), 2 readers on Mendeley (PlumX Metrics)
25. **Doshi P**. US incentive scheme for neglected diseases: a good idea gone wrong? *BMJ* 2014 Jul 21;349:g4665.
4 citations (Scopus), 2 blog and social media mentions (Altmetric), 1 policy document reference (Altmetric), 19 readers on Mendeley (PlumX Metrics), 3158

- full text views on journal website, 350 PDF downloads from journal website, 6 user-generated Bitly links to article with a total of 2 link clicks (PlumX Metrics)*
26. **Doshi P.** EMA policy on transparency is "strikingly" similar to deal struck with drug company, say experts. *BMJ* 2014 Jun 12;348:g3852.
1 citation (Scopus), 16 blog and social media mentions (Altmetric), 3 readers on Mendeley (PlumX Metrics), 606 full text views on journal website, 98 PDF downloads from journal website, 2 user-generated Bitly links to article with a total of 13 link clicks (PlumX Metrics)
 27. **Jefferson T, Doshi P.** Multisystem failure: the story of antinfluenza drugs. *Recent Prog Med* 2014 May;105(5):187-190.
2 citations (Scopus), 11 social media mentions and interactions (PlumX Metrics)
 28. **Doshi P.** From promises to policies: is big pharma delivering on transparency? *BMJ* 2014 Feb 26;348:g1615.
6 citations (Scopus), 60 blog and social media mentions (Altmetric), 1 reader on Mendeley (PlumX Metrics), 1510 full text views on journal website, 345 PDF downloads from journal website, 6 user-generated Bitly links to article with a total of 17 link clicks (PlumX Metrics)
 29. **Doshi P, Groves T, Loder E.** Clinical trial data: get them while you can. *BMJ: British Medical Journal* 2014 01/11;348(7940):8-8.
4 citations (Scopus), 19 social media mentions (Altmetric), 4 readers on Mendeley (PlumX Metrics), 1270 full text views on journal website, 262 PDF downloads from journal website
 30. **Doshi P, Vedula SS, Li T.** Yoda and truth seeking in medicine: Making sense of the curious case of rhBMP-2. *BMJ* 2013;347(7915).
2 citations (Scopus), 12 blog and social media mentions (Altmetric), 4 readers on Mendeley (Altmetric), 967 full text views on journal website, 246 PDF downloads from journal website
 31. **Doshi P, Goodman SN, Ioannidis JP.** Raw data from clinical trials: within reach? *Trends Pharmacol Sci* 2013 Dec;34(12):645-647.
29 citations (Scopus), 1 social media mention (PlumX Metrics), 34 readers on Mendeley (Mendeley.com)
 32. **Doshi P.** Transparency interrupted: the curtailment of the European Medicines Agency's Policy on access to documents. *JAMA Intern Med* 2013 Nov 25;173(21):2009-2011.
7 citations (Scopus), 10 blog and social media mentions (Altmetric), 10 readers on Mendeley (PlumX Metrics), 655 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 89 link clicks (PlumX Metrics)
 33. **Doshi P.** Putting GlaxoSmithKline to the test over paroxetine. *BMJ* 2013 Nov 12;347:f6754.
6 citations (Scopus), 67 blog and social media mentions (Altmetric), 23 readers on Mendeley (Altmetric), 1 Wikipedia reference (PlumX Metrics), 3012 full text views

on journal website, 466 PDF downloads from journal website, 1 full text view in EBSCO databases (PlumX Metrics), 2 user-generated Bitly links to article with a total of 11 link clicks (PlumX Metrics)

34. **Doshi P.** Influenza: marketing vaccine by marketing disease. *BMJ* 2013 May 16;346:f3037.
17 citations (Scopus), 952 social media mentions (Altmetric), 9 news outlet mentions (PlumX Metrics), 72 readers on Mendeley (Altmetric), 36,002 full text views on journal website, 4488 PDF downloads from journal website, 29 user-generated Bitly links to article with a total of 1535 link clicks (PlumX Metrics)
35. **Doshi P,** Jefferson T. Drug Data Shouldn't Be Secret. *New York Times* 2012 04/11;161(55738):1.
0 citations (Scopus)
36. **Doshi P, Akabayashi A.** Japanese Childhood Vaccination Policy. *Camb Q Healthc Ethics* 2010 Jul;19(3):283-289.
5 citations (Scopus), 2 social media mentions (Altmetric), 5 readers on Mendeley (Altmetric), 22 full text views on journal website, 51 PDF downloads from journal website
37. Jefferson T, Jones M, **Doshi P, Del Mar C.** Possible harms of oseltamivir--a call for urgent action. *Lancet* 2009 Oct 17;374(9698):1312-1313.
30 citations (Scopus), 26 readers on Mendeley (Mendeley.com)
38. **Doshi P.** Science in the Private Interest: Has the Lure of Profits Corrupted Biomedical Research? *IEEE Technology & Society Magazine* Spring 2006;25(1):10-11.
0 citations (Scopus), 491 full text views on journal website
39. **Doshi P.** Selling 'pandemic flu' through a language of fear. *Christian Science Monitor* 2006 03/21;98(79):9.
0 citations (Scopus)
40. **Doshi P.** Viral Marketing. *Harper's Magazine* 2006 03;312(1870):54.
0 citations (Scopus)
41. **Doshi P.** Are US flu death figures more PR than science? *BMJ* 2005;331(7529):1412.
13 citations (Scopus), 63 blog and social media mentions (Altmetric), 3 news outlet mentions (Altmetric), 11 readers on Mendeley (Altmetric), 1 YouTube video mention (Altmetric), 12,755 full text views on journal website, 1345 PDF downloads from journal website

2. Letters to the editor in refereed journals

1. **Doshi P,** Spence O*, Powers JH. Noninferiority Trials. *N Engl J Med* 2018 Jan 18;378(3):304. 0 citations (Scopus)

2. Jones M, Del Mar C, **Doshi P**. Findings of an Observational Study of Neuraminidase Inhibitors Highly Sensitive to Decision to Exclude 1652 Treated Patients. *Clin Infect Dis* 2017 Sep 15;65(6):1050. 1 citation (Scopus), 2 readers on Mendeley (PlumX Metrics), 104 PDF downloads from journal website
3. Kuzucan A*, **Doshi P**, Zito JM. Pharmacists can help to end direct-to-consumer advertising. *Am J Health Syst Pharm* 2017 May 15;74(10):640-642. 0 citations (Scopus), 58 social media mentions and interactions (PlumX Metrics), 1 reader on Mendeley (Altmetric), 81 full text views in EBSCO databases (PlumX Metrics)
4. **Doshi P**, Jefferson T. Neuraminidase Inhibitors and Influenza Infection. *JAMA Intern Med* 2016 Mar;176(3):415-416. 0 citations (Scopus), 237 PDF downloads from journal website, 22 readers on Mendeley (PlumX metrics)
5. **Doshi P**, Heneghan C, Jefferson T. Oseltamivir for influenza. *Lancet* 2015 Sep 19;386(9999):1134-1135. 0 citations (Scopus), 1 social media mention (PlumX Metrics)
6. Collignon P, **Doshi P**, Del Mar C, Jefferson T. Safety and efficacy of inactivated influenza vaccines in children. *Clin Infect Dis* 2015 Feb 1;60(3):489. 1 citation (Scopus), 2 social media mentions (Altmetric), 10 readers on Mendeley (PlumX Metrics), 2 Wikipedia references (PlumX Metrics), 61 PDF downloads from journal website
7. Del Mar C, **Doshi P**, Hama R, Jones M, Jefferson T, Heneghan C, et al. Neuraminidase inhibitors for influenza complications. *Lancet* 2014;384(9950):1260-1261. 0 citations (Scopus), 1 social media mention (PlumX Metrics), 20 readers on Mendeley (Mendeley.com)
8. **Doshi P**, Jefferson T. Clinical trials: Tamiflu reviewers respond to critics. *Nature* 2014 May 15;509(7500):288. 1 citation (Scopus), 2 social media mentions (Altmetric), 10 readers on Mendeley (Altmetric), 107 full text views in EBSCO databases (PlumX Metrics), 1 user-generated Bitly link to article with a total of 2 link clicks (PlumX Metrics)
9. **Doshi P**, Jefferson T. Authors' reply to Dunning. *BMJ* 2014 Apr 30;348:g3018. 0 citations (Scopus), 1 reader on Mendeley (PlumX Metrics), 295 full text views on journal website, 87 PDF downloads from journal website
10. **Doshi P**. The importance of influenza vaccination-reply. *JAMA Intern Med* 2014 Apr;174(4):645-646. 0 citations (Scopus), 208 PDF downloads from journal website
11. **Doshi P**, Abi-Jaoude E, Lexchin J, Jefferson T, Thomas RE. Influenza vaccination of health care workers. *CMAJ* 2013;185(2):150. 2 citations (Scopus), 3 readers on Mendeley (Mendeley.com)
12. **Doshi P**. EFPIA-PhRMA's principles for clinical trial data sharing have been misunderstood. *BMJ* 2013;347(7922). 2 citations (Scopus), 5 social media mentions (Altmetric), 1 news outlet mention (Altmetric), 2 readers on Mendeley

(Altmetric), 832 full text views on journal website, 170 PDF downloads from journal website

13. **Doshi P.** The 2009 influenza pandemic. *Lancet Infect Dis* 2013;13(3):193. 1 citation (Scopus), 2 readers on Mendeley (Mendeley.com)
14. **Jones M**, Hama R, Jefferson T, **Doshi P.** Neuropsychiatric adverse events and oseltamivir for prophylaxis. *Drug Saf* 2012 Dec 1;35(12):1187-8; author reply 1188-90. 8 citations (Scopus), 2 readers on Mendeley (PlumX Metrics), 47 full text views in EBSCO databases, 122 PDF downloads from journal website
15. **Heneghan C**, Jefferson T, **Doshi P.** Antivirals for treatment of influenza. *Ann Intern Med* 2012 Sep 4;157(5):385-6; author reply 386-7. 0 citations (Scopus)
16. Cochrane Neuraminidase Inhibitors Review Team. Does oseltamivir really reduce complications of influenza? *Clin Infect Dis* 2011 Dec;53(12):1302-3; author reply 1303-4. 0 citations (Scopus), 33 PDF downloads from journal website
17. **Doshi P**, Jefferson T. WHO and pandemic flu. Another question for GSK. *BMJ* 2010 Jun 29;340:c3455. 2 citations (Scopus), 1 social media mention (PlumX Metrics), 4 readers on Mendeley (PlumX Metrics), 1168 full text views on journal website, 4 PDF downloads from journal website
18. **Jefferson T**, **Doshi P.** WHO and pandemic flu. Time for change, WHO. *BMJ* 2010 Jun 29;340:c3461. 5 citations (Scopus), 1 social media mention (PlumX Metrics), 2 readers on Mendeley (PlumX Metrics), 1343 full text views on journal website, 7 PDF downloads from journal website
19. **Collignon P**, **Doshi P**, Jefferson T. Ramifications of adverse events in children in Australia. *BMJ* 2010 Jun 9;340:c2994. 7 citations (Scopus), 132 social media mentions (Altmetric), 6 readers on Mendeley (PlumX Metrics), 2885 full text views on journal website, 11 PDF downloads from journal website
20. **Doshi P.** Pandemic influenza: severity must be taken into account. *J Infect Dis* 2010 May 1;201(9):1444-1445. 4 citations (Scopus), 5 readers on Mendeley (PlumX Metrics), 19 full text views in EBSCO databases (PlumX Metrics), 13 PDF downloads from journal website
21. **Doshi P.** Doshi responds. *Am J Public Health* 2008;98(11):1928-1930. 0 citations (Scopus), 5 social media mentions (Altmetric)
22. **Doshi P.** Reason for optimism. *BMJ* 2008;336(7637):172. 0 citations (Scopus), 4 readers on Mendeley (PlumX Metrics), 457 full text views on journal website, 95 PDF downloads from journal website
23. **Doshi P.** Popular and scientific attitudes regarding pandemic influenza. *Emerg Infect Dis* 2008 Sep;14(9):1501-2; author reply 1502. 1 citation (Scopus), 4 readers on Mendeley (PlumX Metrics), 176 full text views in EBSCO database (PlumX Metrics)

24. **Doshi P.** Estimation of death rates from pandemic influenza. *Lancet* 2007 Mar 3;369(9563):739; author reply 739-40. 1 citation (Scopus), 12 readers on Mendeley (Mendeley.com)
25. **Doshi P.** Influenza vaccination: policy versus evidence: Policy is in the lead. *Br Med J* 2006;333(7576):1020-1021. 2 citations (Scopus), 5 readers on Mendeley (PlumX Metrics), 982 full text views on journal website, 298 PDF downloads from journal website

3. Referee for professional or scientific journal

1. AHRQ Effective Health Care Program
2. American Journal of Respiratory and Critical Care Medicine
3. American Journal of Public Health
4. Annals of Internal Medicine
5. BMC Medical Research Methodology
6. BMC Public Health
7. BMJ
8. Canadian Medical Association Journal (CMAJ)
9. CNS Drugs
10. Drug and Therapeutics Bulletin
11. European Journal of Pediatrics
12. European Journal of Public Health
13. Expert Review of Vaccines
14. Health Affairs
15. Health Policy
16. Health Technology Assessment (Italian government)
17. Healthcare Policy
18. Influenza and Other Respiratory Viruses
19. JAMA Internal Medicine
20. Journal of Biomedical Research
21. Journal of Clinical Epidemiology
22. Journal of Medical Ethics
23. New England Journal of Medicine
24. PLOS Medicine
25. PLOS ONE
26. Trials
27. World Medical and Health Policy

4. Editorial positions on professional or scientific journals

Associate Editor
The BMJ (www.bmj.com)

2013 – ongoing

Guest editorial board member 2017 – 2018
Scientific Data (www.nature.com/sdata/)

E. Honors and Awards

New Investigator Award 2015
American Association of Colleges of Pharmacy

The Wired Smart List 2013 (UK) 2013
<http://www.wired.co.uk/magazine/archive/2013/12/features/the-smart-list-2013>

Nathan Wolfe/CNN Prize 2013
Johns Hopkins Bloomberg School of Public Health

Siegel Teaching Prize 2011
Massachusetts Institute of Technology

MIT-Japan Program intern 2009
Massachusetts Institute of Technology

Presidential Fellowship 2006 – 2007
Massachusetts Institute of Technology

Noma-Reischauer Prize in Japanese Studies 2006
Graduate Student Essay Prize for “The Lost Lessons of SMON [subacute myelo-optico neuropathy]”
Kodansha Ltd., Publishers and the Reischauer Institute, Harvard University

Joseph Fletcher Memorial Prize for excellence in an A.M. thesis 2006
Harvard University

Summer Foreign Language Assistance Scholarship (FLAS) for Japanese 2004
Harvard University

Best Socio-Cultural Anthropologist 2002
Brown University

Perry Gatson Scholarship Award for Outstanding Achievement in Anthropology 2002
Brown University

3) Service

A. Scientific, Professional and Scholarly Organizations

The BMJ **2013 – indefinite**

The BMJ (formerly the *British Medical Journal*) is an international peer reviewed medical journal. I serve as an associate editor, a paid position, in which capacity I write articles, commission articles, handle manuscripts, and contribute to journal decision making.
International organization; Staff position

Health Canada **2017 – ongoing**

Selected to be on “roster of experts” for Health Canada’s Health Products and Food Branch (HPFB) activated related to the implementation of public release of clinical information
International organization; Volunteer position

European Medicines Agency **Jan - Apr 2013**

Participated in two advisory groups (rules of engagement & good analysis practice) regarding EMA’s draft Policy 0070, Publication of Clinical Trial Data
International organization; Volunteer position

Committee on Publication Ethics **2015 – ongoing**

International organization; Member; 3 years

American College of Cardiology **2013**

Writing committee member on Data Transparency Health Policy Statement
National organization; Volunteer position

AACP **2014 – 2016**

National organization; Member; 2 years

Rho Chi **2017 – ongoing**

Inducted in 2017
National organization; Member; 1 years

Cochrane **2018 – ongoing**

International organization; Member; 5 years

B. Additional professional service

Reagan-Udall Foundation for the FDA **2016 – ongoing**

Unpaid member of IMEDS Steering Committee